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Regulation of calcitriol receptor and its mRNA in normal and renal
failure rats. Homologous up-regulation of calcitriol receptor (VDR) by
calcitriol is believed to be a transcriptional event. In this experiment,
we studied the effect of calcitriol on VDR in normal and renal failure
rats. The time course of the effect of calcitriol on VDR mRNA showed
a biphasic change in VDR mRNA in response to calcitriol. The
concentration of intestinal VDR mRNA increased at six hours and
reached peak levels approximately 15 hours after calcitriol injection.
Thereafter, the mRNA began to decrease and by 48 hours the level had
declined to below the control values. The VDR levels also increased,
though they lagged behind the VDR mRNA, and nearly plateaued at 24
hours after calcitriol treatment. In renal failure, the concentrations of
VDR were lower and the levels of VDR mRNA were higher than the
respective values of normal rats, suggesting that VDR synthesis was
inhibited at post-transcriptional sites. Chronic administration of cal-
citriol increased the VDR but lowered the VDR mRNA levels in both
normal and renal failure rats. Infusion of uremic ultrafiltrate to normal
rats resulted in lower VDR and higher VDR mRNA levels similar to
those found in rats with renal failure. The results indicate that uremic
toxins are responsible for the low VDR and high VDR mRNA in renal
failure.
The genomic action of calcitriol is believed to be mediated
through a hormone-receptor complex interacting with nuclear
chromatin. Interaction of the calcitriol receptor (VDR) with
VDR responsive genes produces the bioactive proteins that
carry out the biological action of calcitriol [1]. Therefore,
regulation of VDR concentration modulates cellular responsive-
ness to calcitriol, for the genomic action of calcitriol is propor-
tional to the cellular receptor numbers [21. In renal failure, the
concentration of VDR is decreased [3, 4]; therefore, the biolog-
ical response to calcitriol could be diminished. For example,
intestinal calcium absorption in response to a pharmacological
dose of calcitriol is lower in nephrectomized rats than in normal
rats [5, 6]. Furthermore, parathyroid hormone (PTH) levels are
elevated despite normal plasma concentrations of calcitriol [7],
and long-term administration of calcitriol fails to normalize
PTH levels [8].
Recent studies have shown that calcitriol increases VDR and
VDR mRNA concentrations [9, 10], suggesting that calcitriol
up-regulates its own receptor. Other studies, however, were
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unable to show that the up-regulation of VDR is associated with
an increased VDR mRNA [11, 12]. Regulation of VDR level in
renal failure, however, has not been thoroughly studied. There-
fore, in this study, we examined the effect of calcitriol on
intestinal VDR and its mRNA in normal rats and in rats with
renal failure. Our study showed that calcitriol induced a bi-
phasic change in VDR mRNA. VDR mRNAs increased initially
and followed by a decline to levels below the control values.
Further, uremic toxins appeared to inhibit the VDR synthesis at
post-transcriptional sites.
Methods
Male Sprague-Dawley rats weighing 200 g were used for the
present study. Renal failure was achieved by subtotal nephrec-
tomies under ether anesthesia. One kidney was removed
through flank incision and two-thirds of the other kidney was
removed three days later. Control rats had sham nephrecto-
mies. Animals were pair-fed a regular Purina rat chow contain-
ing 1.0% Ca, 0.8% P, and 4.5 IU per g vitamin D. Intestinal
VDR and VDR mRNA and plasma concentrations of creatinine,
calcitriol, calcium, and phosphorus were measured at the end of
the experiments described below.
Time course of the effect of calcitriol on intestinal VDR and
VDR mRNA in normal rats and renal failure rats
Five rats underwent subtotal nephrectomies, and another five
rats had sham nephrectomies to serve as controls for the
following studies. Animals were pair-fed for one week after the
surgery. One control rat and one subtotally nephrectomized rat
received vehicle (1.25% ethanol in propylene glycol) through
the tail veins. They were killed immediately and intestinal VDR
and VDR mRNA were measured to represent the values at time
0. Three control rats and three renal failure rats received 50 ng
of calcitriol intravenously (i.v,; this was an arbitrarily chosen
dose and equivalent to tenfold calcitriol production rate/day of
a 200 g rat [13]), and intestinal VDR and VDR mRNA were
measured at time 6, 15, and 24 hours after calcitriol injection
(one rat for each time point for both control and renal failure).
Another two rats (one control and one renal failure) were
intravenously injected with a 50 ng of calcitriol at time 0 and 24
hours. Intestinal VDR and VDR mRNA were measured 48
hours after the first calcitriol injection.
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Effect of calcitriol on intestinal VDR and VDR mRNA on
normal rats
Five normal rats were injected i.v. with 3 ng of calcitriol once
a day for two days and another five rats were injected i.v. with
50 ng of calcitriol once a day for two days. Control rats (N = 5)
were injected with vehicle once a day for two days to serve as
controls. All rats were killed for measurement of intestinal VDR
and VDR mRNA 48 hours after the initial injection of vehicle or
calcitnol.
Effect of calcitriol on intestinal VDR and VDR mRNA in rats
with renal failure
Group 1. Five control rats and five renal failure rats were
injected i.v. with vehicle for two days. Five renal failure rats
were injected with 3 ng/day of calcitriol for two days. This dose
of calcitriol was equivalent to the average difference in calcitriol
production rate between the subtotally nephrectomized rats and
control animals [131. Another five renal failure rats received
50 ng/day of calcitriol for two days.
Group 2. Five control rats and six renal failure rats were
infused subcutaneously for seven days with vehicle by osmotic
minipumps implanted subcutaneously between the scapulae.
Another six renal failure rats were infused subcutaneously for
seven days with 3 ng/day of calcitriol by osmotic minipumps.
Effect of uremic plasma ultrafiltrate on intestinal VDR and
VDR mRNA
We have previously demonstrated that infusion of uremic
plasma ultrafiltrate suppressed intestinal VDR concentration
[4]. In this experiment, we studied the effect of uremic toxins on
VDR mRNA. Four normal rats were infused for 20 hours
intravenously through femoral vein catheter with 30 ml of
normal plasma ultrafiltrate. Another four normal rats were
infused for 20 hours with 30 ml of uremic plasma ultrafiltrate as
described previously [4]. Uremic ultrafiltrates were collected at
the initiation of dialysis. Normal plasma ultrafiltrates were
obtained by filtering pooled heparinized plasma through an
identical dialyzer used for collecting uremic ultrafiltrates [14].
The ultrafiltrate electrolytes were adjusted to the following
concentrations: Na 131 mEq/liter, K 2.7 mEq/liter, Ca 4.6
mgldl, Mg 1.66 mg/dl, P4.35 mg/dl, urea nitrogen 18 mg/dl, and
creatinine 0.93 mg/dl for the normal plasma ultrafiltrate, and Na
131 mEq/liter, K 2.7 mEq/liter, Ca 4.4 mgldl, Mg 1.66 mg/dl, P
4.55 mgldl, urea nitrogen 113 mg/dl, and creatinine 10.4 mg/dl
for the uremic ultrafiltrate.
Measurement of intestinal VDR. Rats were decapitated and
the initial 20 cm of small intestine distal to the pylorus (duode-
num and portion of jejunum) was removed and flushed with
ice-cold Ca/Mg-free phosphate (6.6 mrt Na2HPO4, 250 IU/ml
Trasylol and 1.5 ifiM KH2PO4)-buffered saline (CMF-PBS). The
intestine was split longitudinally in half. One-half was used for
VDR measurement, and the other half was used for VDR
mRNA measurement as described below. The mucosal cells
were scraped from the serosa, washed three times in 20
volumes of CMF-PBS and centrifuged at 200 X g for five
minutes after each washing. The tissue was homogenized by a
Polytron in 20 vol (wt/vol) of buffer consisting of 300 mri KCI,
200 pg/ml soybean trypsin inhibitor, 10 m Tns-HC1 (pH 7.4),
1 mM EDTA, 10 m sodium molybdate, and 5 m dithiothreitol
(KTEDM) [15]. Cytosol was prepared by centrifugation at
100,000 x g for 45 minutes at 0 to 4°C. Cytosol protein
concentration was determined by the Bradford method.
Measurement of intestinal receptor concentration. We have
previously determined intestinal VDR binding characteristics
[4]. Scatchard analysis indicated a single binding site with an
apparent kD of 0.44 nM, a value nearly identical to 0.47 flM
reported by others [16]. Therefore, in this study we only
measured Nmax of VDR (total concentration of binding sites).
Nmax of VDR was assessed by incubating cytosolic protein for
three hours at 0 to 4°C with a saturating concentration of
tritiated calcitriol (5 nM) in the presence or absence of a 100-fold
excess of cold calcitriol [4]. Bound hormone was separated
from free hormone by adsorption of free hormone to dextran-
coated charcoal (0.2% dextran, 2.0% charcoal in 10 mr.t Tris-
HCI, 1.0 mrs EDTA, pH 7.4) for 15 minutes on ice, followed by
centrifugation at 1,600 x g. Supernatants (0.25 ml) were
counted with a scintillation counter. Nonspecific binding was
determined in each sample of cytosolic protein from the radio-
activity that remained in the bound fraction after incubation in
the presence of a 100-fold excess of cold calcitriol. Specific
binding of calcitriol was calculated by subtracting nonspecific
binding from total binding.
Measurement of VDR mRNA. Intestinal cellular RNA was
extracted by the guanidinium thiocyanate-phenol-chioroform
extraction method of Chomczynski and Sacchi [17]. RNA was
quantitated by determining absorbance of the sample at 260/280
nm (Beckman model DU 62 Spectrophotometer). Polyadeny-
lated RNA was extracted by oligo(dT)-affinity chromatography
as described by Maniatis, Fritsch and Sambrook [18]. Two
hundred milligrams of oligo(dT)-cellulose (Boehringer Mann-
helm Biochemicals) were equilibrated in 10 ml lx binding
buffer [100 m sodium citrate pH 7.0, 0.5 M LiC1, 1 m EDTA,
0.1% SDS (sodium dodecyl sulfate)] in a disposable column.
Two mg of total cellular RNA were brought to a volume of 2.4
ml with sterile water and heated to 65°C for five minutes. The
samples were then cooled on ice and 2.4 ml 2 x binding buffer
was added to each sample and applied to the oligo(dT)-cellulose
column. The effluent was collected and reapplied to the column.
Each column was then washed with 20 volumes of 1 x binding
buffer. The Polyadenylated RNA was eluted from the column
with 4 volumes of elution buffer (10 mrt Tris-HC1 pH 7.6, 1 mM
EDTA, 0.05% SDS). 0.1 volumes of 3 M sodium acetate, pH
5.2, and 2.5 volumes of ice-cold ethyl alcohol were then added
to each sample, mixed and placed at —20°C for one hour. The
samples were then centrifuged at 10,000 x g for 20 minutes at
4°C, supernatant discarded, and pellet washed with 70% ethyl
alcohol. The ethyl alcohol was aspirated and the pellet dried by
speedvac. The pellet was dissolved in 50 sl sterile water and its
absorbance was determined at 260 and 280 nm.
Northern blot analysis. Poly(A)+ RNA, S g, was fraction-
ated under denaturing conditions on a 1.2% formaldehyde-
agarose gel and transferred to Biotrans Nylon Membranes (ICN
Corporation, Irvine, California, USA) by diffusion blotting as
described by Maniatis et al [18]. VDR mRNA was determined
from the migration of 18s and 28s nbosomal RNA. The mem-
branes were baked for two hours at 80°C to cross link RNA to
membranes. The membranes were then prehybridized for two
hours at 42°C in hybridization solution containing 50% forma-
mide, 5X Denhardts solution, 0.5% SDS, SX SSC (SSC =
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0.15 M NaCL, 0.015 M sodium citrate, pH 7.0) and 100 jg/m1
sonicated herring sperm DNA. Hybridization was carried out
for 18 hours at 42°C in 4 to 10 ml fresh hybridization solution to
which 1 x 106 cpm/ml 32P-labeled probe was added. Filters
were briefly rinsed in 200 ml 2X SSC at room temperature and
then washed four times each for 15 minutes at 42°C in 500 ml of
0. LX SSC, 0.1% SDS. For autoradiographs, the membranes
were exposed to XOMAT X-ray films (Eastman Kodak Co.,
Rochester, New York, USA) with intensifying screens for 2 to
120 hours at —80°C. Northern blot hybridization showed that
VDR mRNA ran as a single band at 4.4 kb for each sample
before performing dot blot hybridization.
Dot blot hybridization was performed according to the
method of Church and Gilbert [19]. Poly(A) + RNA was serially
diluted in 25 m sodium phosphate buffer pH 7.0 to produce
samples containing 0.625, 1.25, 2.5 and 5.0 g RNA, and
blotted onto nylon membranes (Biotrans, ICN Corp., Irvine,
California, USA) that had been pre-equilibrated in 25 mM
sodium phosphate buffer pH 7.0 using a Minifold I microsample
filtration manifold (Schleicher and Schuell, Keene, New Hamp-
shire, USA). The filters were dried at room temperature for
thirty minutes and then baked at 80°C for two hours. Prehybrid-
ization was carried out as described above. The membranes
were then hybridized with the cDNA probe for human VDR (a
gift of Dr. Mark R. Haussler, University of Arizona, Tucson,
Arizona, USA). A 2.1 kilobase human VDR insert from the
EcoR I site of pGem 4 and a 2.1 kilobase chick /3-actin cDNA
insert from the HIND II site of pBR322 were obtained by
restriction enzyme digestion of the respective plasmid prepara-
tion. Each cDNA was labeled to a specific activity of 108 to io
cpmlmg DNA according to the oligo-priming method of Fein-
berg and Vogelstein [20] using a random primed DNA labeling
kit (Boehringer Mannheim, Indianapolis, Indiana, USA).
The dot intensities of the autoradiographs of varying expo-
sures were quantitated by densitometry with the Bio-Rad
Model 620 Video Densitometer equipped with the 2-D Analyst
II data analysis software (BIO-RAD Laboratories, Richmond,
California, USA). The amount of VDR mRNA in each blot was
quantitated relative to the amount of /3-actin mRNA. All the
results were expressed as percent of the controls obtained from
dot blot hybridization.
Other analytical methods. Calcium concentration was mea-
sured by atomic absorption spectrophotometry (model 306;
Perkin Elmer, Norwalk, Connecticut, USA). The concentration
of creatinine and phosphorus were measured as described
previously [13]. Plasma calcitriol was measured in duplicate
using a radioreceptor assay [21]. The intra-assay coefficients of
variation were 5.4% for low control (20 pg/ml, N =6) and 4.7%
for high control (100 pg/mI, N = 6). The inter-assay coefficients
of variation were 7% for low (N = 12) and 4.1% for high control
(N = 12).
All data were expressed as mean SEM. Statistical analysis
was performed using Student's t-test and Duncan's multiple
range test. A P value of less than 0.05 was considered signifi-
cant.
Results
Time course of the effect of calcitriol on intestinal VDR and
VDR mRNA in normal rats and renal failure rats
Plasma creatinine of normal rats ranged from 0.57 to 0.63
mg/dl (N = 5) and the levels were increased in rats with renal
failure ranging from 1.23 to 1.40 mg/dl (N = 5). Figure 1 shows
the plasma concentrations of calcitriol in rats injected with
calcitriol. The level was lower in the rat with renal failure (54.1
pg/ml) than that of the control rat (74.3 pg/ml) at time 0.
Following 50 ng calcitriol injection, plasma levels of calcitriol
were higher at each time point in rats with renal failure, possibly
due to their lower clearance rate of calcitriol [22]. The expres-
sion of VDR mRNA of control and renal failure rats increased
steadily and peaked at 15 hours, thereafter the levels began to
decrease and by 48 hours after calcitriol injection the levels had
declined to 54% (normal rat) and 59% (renal failure rat) of their
respective controls (at time 0). The increment of VDR lagged
slightly behind the rising VDR mRNA. However, the levels
increased rapidly during the first 24 hours and nearly plateaued
24 hours after calcitriol injection. The concentrations of VDR
remained lower in rats with renal failure compared to normal
rats, even though their plasma levels of calcitriol were higher
after injection of calcitriol.
Effect of calcitriol on intestinal VDR and VDR mRNA on
normal rats
Figure 2 illustrates the results of plasma calcitriol and the
levels of VDR mRNA and VDR in normal rats injected with
3 ng/day and 50 nglday of calcitriol for two days. Plasma
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Fig. 1. Time course of the effect of calcitriol
on VDR (- - -) and VDR mRNA (—) in
normal (0) and renal failure (•) rats injected
with 50 ng/day of calcitriol for two days (B).
VDR and VDR mRNA were measured at time
0, 6. 15, 24, and 48 hours after calcitriol
injection (one animal for each time point for
control and renal failure). Plasma calcitriol
concentrations of each time point of these
animals are plotted on A.
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Fig. 2. Plasma concentration of calcitriol and
intestinal VDR mRNA and VDR of normal
rats injected with vehicle or calcitriol daily for
two days. I, normal rats injected with vehicle
(N 5); 2, normal rats injected with 3 ng/day
calcitriol (N = 5); 3, normal rats injected with
50 nglday calcitriol (N = 5). P values refer to
comparison between the control (1) and2 3 experimental groups (2 or 3). * P < 0.001.
Table 1. Plasma concentrations of creatinine, calcium and
phosphorus in normal rats injected with calcitriol for two days
Cr mg/dl 'ca mg/dl Pp mg/dl
1. Normal rats
÷ vehicle x 2 days 0.57 0.01 9.28 0.05 7.09 0.16(N=5)
2. Normal rats
+ 3 ng/day x 2 days 0.57 0.02 9.78 0.07 6.84 0.09
(N =5)
3. Normal rats
+ 50 fig/day x 2 days 0.59 0.02 10.96 0.24 7.21 0.24(N=5)
P values
1 vs. 2 NS <0.001 NS
1 vs. 3 NS <0.001 NS
2 vs. 3 NS <0.001 NS
Abbreviations are: PCr, plasma creatinine; pc0, plasma calcium; P,
plasma phosphorus.
concentrations of calcitriol were not increased after 3 ng/day of
calcitriol injection (86.4 2.0 vs. 85.0 2.1 pg/ml of controls
injected with vehicles). This is probably due to the fact that
calcitriol accelerates its own degradation [13], so that the small
dose of calcitriol did not raise plasma levels of calcitriol. The
levels, however, increased significantly after 50 nglday of
injection (165.5 3.7 pg/mI, P <0.001). Similar to the results
shown in Figure 1, 48 hours after calcitriol injection VDR
mRNA decreased and VDR increased significantly. The VDR
was greater in animals injected with a higher dose of calcitriol
(group 2 vs. 3, P < 0.001, Fig. 2).
Table 1 summarizes the plasma concentrations of creatinine,
calcium and phosphorus of normal rats injected with calcitriol
or vehicle. Plasma calcium levels were increased, whereas
phosphorus levels did not change after injection of calcitriol.
Effect of calcitriol on intestinal VDR and VDR mRNA in rats
with renal failure
The effect of calcitriol on VDR mRNA and VDR in renal
failure two days after calcitriol injection are summarized in
Figure 3. Plasma levels of calcitriol in animals injected with
vehicle were significantly lower in renal failure rats as com-
pared to normal rats (87.6 2.2 vs. 50.6 1.3 pg/mI, P <
0.001). The levels increased significantly in rats injected with
3 nglday and SOng/day of calcitriol (71.4 1.7 pglml and 194.3
6.7 pg/ml, both P <0.005), though the levels of rats injected
with 3 ng/day were still lower than those of normal rats injected
with vehicle (P < 0.005).
The concentrations of VDR mRNA in rats injected with
vehicle were significantly higher in renal failure (124.8 3.2 vs.
100 4.3%, P < 0.005) compared to the controls. Following
calcitriol injection, VDR increased and the increase was greater
in animals injected with a higher dose of calcitriol. However,
VDR mRNA decreased to nearly the same level in renal failure
rats injected with 3 nglday and 50 nglday of calcitriol.
Plasma concentrations of creatinine, calcium and phosphorus
of renal failure rats injected with two days of calcitriol are
tabulated in Table 2. Plasma concentration of calcium increased
significantly in renal failure rats after calcitriol injection,
whereas plasma phosphorus levels were not different between
normal rats and renal failure rats with or without calcitriol
injection.
Chronic infusion of calcitriol (seven days) and its effect on
VDR mRNA and VDR are depicted on Figure 4. Plasma
calcitriol of rats with renal failure increased significantly after
seven days of calcitriol infusion. However, the levels (72.8
1.5 pg/mI) remained lower than those of the controls infused
with vehicle (87.3 0.8 pg/mI, P < 0.001). Despite the lower
plasma concentrations of calcitriol, the VDR of rats with renal
failure (222.2 6.0 fmollmg protein) increased to levels (365.0
19.0 fmol/mg protein) greater than those of the controls (326.2
10.4 fmollmg protein, P < 0.005) after seven days of calcitriol
supplementation. The levels of VDR mRNA of rats with renal
failure (137.4 4,5%, P < 0.001) were higher than the controls
without calcitriol supplementation. The levels (80.5 1.3%)
also decreased significantly after calcitriol infusion.
Table 3 summarizes plasma creatinine, calcium and phospho-
rus of rats infused with 3 ng/day calcitriol for seven days.
Plasma calcium and phosphorus levels were not different be-
tween renal failure rats infused with vehicle and calcitriol.
Effect of uremic plasma ultrafiltrate on intestinal VDR
mRNA and VDR in normal rats
Our previous study [4] led us to believe that uremic toxins are
partly responsible for the decreased VDR concentration in renal
failure, therefore, we studied the effect of uremic ultrafiltrate on
the concentration of VDR mRNA and VDR. Figure 5 summa-
rized the results of the study. Plasma calcitriol [23, 24] and
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Fig. 3. Plasma concentration of ca!citriol and
intestinal VDR mRNA and VDR of normal
and renal failure rats injected with vehicle or
calcitriol daily for two days. 1, normal rats
injected with vehicle (N = 5); 2, renal failure
rats injected with vehicle (N = 5); 3, renal
failure rats injected with 3 ng/day calcitriol
(N = 5); 4, renal failure rats injected with 50
ng/day calcitriol (N = 5). P values refer to
comparison between the control (1) and the
experimental groups (2, 3 or 4). * P < 0.001;2 3 4 ** P < 0.005; and *** P < 0.05.
Table 2. Plasma concentrations of creatinine, calcium and
phosphorus in renal failure rats injected with calcitriol for two days
1Cr mg/dl Ca mg/dl Pp mg/dl
I. Normal rats
+ vehicle x 2 days 0.55 0.02 9.52 0.04 6.76 0.13
(N =5)
2. Renal failure rats
+ vehicle x 2 days 1.27 0.02 9.44 0.06 6.82 0.14(N = 5)
3. Renal failure rats
+ 3 ng/day x 2 days 1.27 0.04 9.72 0,07 6.47 0.08(N=5)
4. Renal failure rats
+ 50 ng/day x 2 days 1.30 0.03 10.66 0.05 6.86 0.14(N=5)
P values
1 vs. 2 <0.001 MS NS
1 vs. 3 <0.001 NS NS
I vs. 4 <0.001 <0.001 NS
2 vs. 3 NS <0.005 NS
2 vs. 4 NS <0.001 NS
3 vs. 4 MS <0.001 NS
Abbreviations are in Table 1.
intestinal VDR decreased [4] as we have previously demon-
strated, whereas VDR mRNA increased significantly after
infusion of uremic ultrafiltrate.
Discussion
In chronic renal failure, the concentration of VDR has been
reported to be decreased in parathyroid gland [3, 25, 26] and
intestine [4]. Several possible mechanisms are proposed for
decreased concentration of VDR in renal failure: (1) Because
calcitriol is known to up-regulate its own receptor [27], the low
plasma calcitriol concentration in renal failure could down-
regulate the VDR. (2) Accumulation of uremic toxins in renal
insufficiency could reduce VDR concentration, as we have
found that infusion of uremic ultrafiltrate to normal rats sup-
presses the concentration of intestinal VDR [4]. (3) A high level
of plasma PTH in renal failure may decrease the concentration
of VDR. The hormone down-regulates VDR and VDR mRNA
in vitro in ROS 17/2.7 cells. It also blocks calcitriol-induced
up-regulation of VDR of intestine and kidney in normal rats
[28]. Furthermore, elevation of PTH secondary to calcium
deficiency is associated with a significant down-regulation of
kidney VDR despite a high concentration of plasma calcitriol
[29]. Taken together, uremic toxins, a high concentration of
plasma PTH, and a low concentration of plasma calcitriol could
reduce VDR level in renal failure.
Homologous up-regulation of VDR by calcitriol is believed to
be a transcriptional event, although this issue remains contro-
versial. Strom et al have demonstrated that calcitriol increases
the concentration of intestinal receptor as well as receptor
mRNA in vitamin D depleted rats [10]. Others, however, were
unable to demonstrate calcitriol induced up-regulation of VDR
in cultured bovine parathyroid cells [30]. Furthermore, up-
regulation of VDR is not always associated with an increased
intestinal VDR mRNA in vivo [11]. In tissue culture system,
calcitriol increased both VDR and VDR mRNA in ROS cells 18
hours after calcitriol treatment [28]. Our time course effect of
calcitriol on intestinal VDR mRNA (Fig. 1) showed a biphasic
change in VDR mRNA in response to calcitriol. The concen-
tration of intestinal VDR mRNA increased at six hours and
reached peak levels approximately 15 hours after calcitriol
injection. Thereafter, the mRNA began to decrease and by 48
hours the level had declined to levels below the control values.
The reason for the decreased VDR mRNA after calcitriol
treatment is not clear. Lower levels of VDR mRNA after
calcitriol treatment have also been reported previously by other
investigators [31, 32].
A recent study has shown that there was no difference in the
levels of VDR mRNA in parathyroid glands between control
and 5/6 subtotally nephrectomized rats [32]. In contrast, we
have shown that the levels of intestinal VDR mRNA were
higher in rats with renal failure than those of control rats. The
reason for this discrepancy could be due to different organs
studied. The levels of intestinal VDR mRNA were also elevated
in normal rats infused with uremic ultrafiltrate, suggesting that
uremic toxins were responsible for the elevated intestinal VDR
mRNA level in renal failure. Despite the higher level of intes-
tinal VDR mRNA the concentrations of intestinal VDR in renal
failure were lower than those of control rats. This finding
appears to indicate that VDR synthesis in renal failure is
inhibited at post-transcriptional site.
The concentrations of intestinal VDR also increased, though
lagged few hours behind the VDR mRNAs, following calcitriol
treatment. The levels nearly plateaued at 24 hours even though
VDR mRNAs were declining during this period (Fig. 1). The
time course effect of calcitriol suggests that the initial regulation
of intestinal VDR appeared to be a transcriptional process, but
it is not clear why VDR continued to increase inspite of
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Fig. 4. Plasma concentration of calcitrio! and
intestinal VDR mRNA and VDR of normal
rats infused with vehicle or calcitriol daily for
seven days. 1, normal rats infused with
vehicle (N = 5); 2, renal failure rats infused
with vehicle (N = 6); 3, renal failure rats
infused with 3 ng/day calcitriol (N = 6). P
values refer to comparison between the
control (1) and the experimental groups (2 or
2 3 3).*P<0.001.
Table 3. Plasma concentrations of creatinine, calcium and
phosphorus in renal failure rats infused with calcitriol for seven days
1cr mg/d! 'Ca mg/dl P mg/dl
1. Normal rats
+ vehicle x 7 days 0.59 0.02 9.78 0.09 6.54 0.22
(N =5)
2. Renal failure rats
+ vehicle x 7 days 1.28 0.03 9.53 0.08 6.38 0.18(N = 6)
3. Renal failure rats
+ 3 ng/day x 7 days 1.27 0.02 9.50 0.15 6.94 0.15(N = 6)
P values
I vs. 2 <0.001 NS NS
1 vs. 3 <0.001 NS NS
2vs.3 NS NS NS
Abbreviations are in Table 1.
declining VDR mRNA. Calcitriol could reduce VDR degrada-
tion thereby increasing its concentration, as it has been shown
that calcitriol prolongs the half-life of VDR in LLC-PK1 cells
[331.
In the present study we have also shown that calcitriol
up-regulated intestinal VDR in renal failure. Supplementation
of 3 ng/day of calcitriol for two days increased VDR levels in
renal failure, though the levels remained lower than the con-
trols. Calcitriol injection also slightly increased the plasma
concentration of calcium in these animals (Table 2). Raising
plasma calcium concentration could up-regulate VDR, as it has
been demonstrated that normalizing plasma calcium levels in
vitamin D deficient rat either by dietary calcium or vitamin D
supplementation increased the concentration of renal VDR [34].
Changes in plasma phosphorus, however, did not alter the renal
VDR concentration [34]. Our failure to up-regulate intestinal
VDRs in renal failure rats to the control levels (Fig. 3) could be
due to an inadequate supplementation of calcitriol, as their
plasma levels remained lower than the controls. The high PTH
level [29] and the presence of uremic toxins [4] in renal failure
may also block calcitriol induced VDR synthesis. However, the
concentrations of intestinal VDR exceeded those of control
animals after seven days of supplementation, even though the
plasma levels of calcitriol remained lower. Apparently the
synthesis of intestinal VDR overcame the inhibitory effect of
PTH and uremic toxins after a long-term supplementation of
calcitriol.
We have also confirmed our previous study [4] that uremic
toxins reduce intestinal VDR concentration. Infusion of uremic
ultrafiltrate for 20 hours to normal rats reduces their VDR
concentration [4]. Although uremic ultrafiltrate suppresses cal-
citriol synthesis [14], decreased calcitriol synthesis can not
entirely account for the decreased VDR concentration, because
the up-regulation of VDR by a pharmacological dose of cal-
citriol (20-fold of the daily production rate) is also blocked by
uremic toxins [4]. Furthermore, as shown in Figure 1, the
concentrations of VDR remained lower in rats with renal failure
than those of normal rats even though the plasma levels of
calcitriol were higher in renal failure rats injected with 50 nglday
of calcitriol. This supports the contention that uremic toxins
inhibited the up-regulation of calcitriol induced VDR.
In summary, in renal failure the concentrations of intestinal
VDR were lower and the levels of VDR mRNA higher than the
respective values of normal rats. These findings suggest that
VDR synthesis is inhibited at translational sites in renal failure.
Calcitriol increased the intestinal VDR levels in normal and
renal failure rats. However, the response of intestinal VDR
mRNA to calcitriol is biphasic. The VDR mRNA levels in-
creased initially but decreased later in normal as well as renal
failure rats. Infusion of uremic ultrafiltrate to normal rats
resulted in lower intestinal VDR and higher VDR mRNA levels,
suggesting that uremic toxins are responsible for the lower
intestinal VDR and higher VDR mRNA in renal failure. The
reasons for higher VDR mRNA in renal failure despite lower
plasma calcitriol is not clear. Nuclear run-on experiments may
clarify this paradoxical finding.
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